Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Rybak

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Treatment of pseudomonal endocarditis with high-dose aminoglycosidesM J Rybak, S C Boike, P W Bush
Antimicrobial Agents and Chemotherapy|October 3, 1998
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetationsJ R Aeschlimann, M J Zervos, M J Rybak
Antimicrobial Agents and Chemotherapy|March 18, 2000
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strainsM J Rybak, E Hershberger, T Moldovan, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methodsE Hershberger, J R Aeschlimann, T Moldovan, et al.
Drug Intelligence & Clinical Pharmacy|January 1, 1983
Zomepirac-related acute renal failureS C Boike, M J Rybak, J E Tintinalli, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, G P Allen, E Hershberger, et al.
Pharmacotherapy|November 11, 1999
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycosideK R Murry, P S McKinnon, B Mitrzyk, et al.
The Journal of Antimicrobial Chemotherapy|April 1, 1988
Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureusP H Chandrasekar, D P Levine, S Price, et al.
Pharmacotherapy|January 1, 1994
Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureusD Stanley, B J McGrath, K C Lamp, et al.
Therapeutic Drug Monitoring|January 1, 1988
Comparison of serum sampling methods for determining vancomycin dosage regimensL M Albrecht, M J Rybak, S C Boike, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
Drug Intelligence & Clinical Pharmacy|September 1, 1982
Treatment of pseudomonal endocarditis with high-dose aminoglycosidesM J Rybak, S C Boike, P W Bush
Antimicrobial Agents and Chemotherapy|October 3, 1998
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetationsJ R Aeschlimann, M J Zervos, M J Rybak
Antimicrobial Agents and Chemotherapy|March 18, 2000
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strainsM J Rybak, E Hershberger, T Moldovan, et al.
Antimicrobial Agents and Chemotherapy|February 27, 1999
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methodsE Hershberger, J R Aeschlimann, T Moldovan, et al.
Drug Intelligence & Clinical Pharmacy|January 1, 1983
Zomepirac-related acute renal failureS C Boike, M J Rybak, J E Tintinalli, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, G P Allen, E Hershberger, et al.
Pharmacotherapy|November 11, 1999
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycosideK R Murry, P S McKinnon, B Mitrzyk, et al.
The Journal of Antimicrobial Chemotherapy|April 1, 1988
Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureusP H Chandrasekar, D P Levine, S Price, et al.
Pharmacotherapy|January 1, 1994
Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureusD Stanley, B J McGrath, K C Lamp, et al.
Therapeutic Drug Monitoring|January 1, 1988
Comparison of serum sampling methods for determining vancomycin dosage regimensL M Albrecht, M J Rybak, S C Boike, et al.
Pageof 14